1. Home
  2. TENX vs GLV Comparison

TENX vs GLV Comparison

Compare TENX & GLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.83

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Logo Clough Global Dividend and Income Fund of beneficial interest

GLV

Clough Global Dividend and Income Fund of beneficial interest

HOLD

Current Price

$5.84

Market Cap

72.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
GLV
Founded
1967
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
71.1M
72.5M
IPO Year
2001
2004

Fundamental Metrics

Financial Performance
Metric
TENX
GLV
Price
$1.83
$5.84
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $29.67
N/A
AVG Volume (30 Days)
★ 3.9M
32.0K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$5.77
52 Week High
$19.40
$6.65

Technical Indicators

Market Signals
Indicator
TENX
GLV
Relative Strength Index (RSI) 27.10 33.44
Support Level $1.31 $5.84
Resistance Level $2.22 $6.37
Average True Range (ATR) 0.12 0.07
MACD 0.32 -0.01
Stochastic Oscillator 5.95 12.07

Price Performance

Historical Comparison
TENX
GLV

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About GLV Clough Global Dividend and Income Fund of beneficial interest

Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.

Share on Social Networks: